Fulcrum Therapeutics (FULC) Enterprise Value (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Enterprise Value of -$318.8 million for Q2 2026, down 648.66% year-over-year from $58.1 million in Q2 2025, and up 4.34% quarter-over-quarter from -$333.3 million in Q1 2026.
Fulcrum Therapeutics (FULC) Enterprise Value (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Enterprise Value for 9 consecutive years, with -$318.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Enterprise Value fell 648.66% year-over-year to -$318.8 million; the TTM figure through Jun 2026 stood at -$318.8 million (down 648.66% YoY), while the FY2025 annual figure was -$352.3 million, down 46.17% from the prior year.
- Enterprise Value rose to -$318.8 million in Q2 2026 per FULC's latest filing, from -$333.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$30.1 million in Q3 2023 and bottomed at -$352.3 million in Q4 2025.
- Historically, Enterprise Value has averaged -$125.8 million across 5 years, with a median of -$57.6 million in 2024.
- Annual changes were most pronounced in 2022 — Enterprise Value surged 66.93% — and 2026, when it tumbled 690.26%.
- Fulcrum Therapeutics' Enterprise Value stood at -$35.1 million in 2022, then sank by 573.03% to -$236.2 million in 2023, then slipped by 2.03% to -$241.0 million in 2024, then plunged by 46.17% to -$352.3 million in 2025, then climbed by 9.5% to -$318.8 million in 2026.
- Business Quant data shows FULC's Enterprise Value at -$318.8 million in Q2 2026, -$333.3 million in Q1 2026, and -$352.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | -318.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -318.84 Mn |
| Mar 31, 2026 | -50.26 Mn |
| Dec 31, 2025 | -197.53 Mn |
| Sep 30, 2025 | -47.08 Mn |
| Jun 30, 2025 | -214.11 Mn |
| Mar 31, 2025 | -42.18 Mn |
| Dec 31, 2024 | -241.02 Mn |
| Sep 30, 2024 | -72.63 Mn |
| Jun 30, 2024 | -86.70 Mn |
| Mar 31, 2024 | -39.95 Mn |
| Dec 31, 2023 | -236.22 Mn |
| Sep 30, 2023 | -30.08 Mn |
| Jun 30, 2023 | -33.97 Mn |
| Mar 31, 2023 | -34.73 Mn |
| Dec 31, 2022 | -35.10 Mn |
| Sep 30, 2022 | -90.94 Mn |
| Jun 30, 2022 | -40.15 Mn |
| Mar 31, 2022 | -33.31 Mn |
| Dec 31, 2021 | -35.41 Mn |
| Sep 30, 2021 | -65.47 Mn |